SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics. Its pipeline includes galinpepimut-S (GPS), a WT1-targeted peptide immunotherapy, and SLS009 (tambiciclib), a selective CDK9 inhibitor, with development activities centered on hematologic malignancies and solid tumors.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueGPS is a WT1-directed peptide immunotherapy being developed for multiple cancer indications.
SLS009 is a selective CDK9 inhibitor being developed as a cancer therapeutic.
Research and clinical trial activities supporting pipeline advancement and regulatory preparation.
Revenue from out-licensing or partnering arrangements such as the 3D Medicines Agreement.
Customers
SELLAS does not sell commercial medicines; its direct counterparties are typically pharmaceutical partners, research collaborators, and licensing counterparties. The eventual end users of its therapies would be oncology patients treated through hospitals, cancer centers, and specialist physicians if products are approved.
Buy or license development and commercialization rights to oncology assets such as GPS or SLS009.
Run the company’s studies and generate the data needed for regulatory filings and partnering.
Future end users of approved therapies in AML, blood cancers, and solid tumors.
Potential partners for territory-specific licensing, co-development, or marketing rights.
Strategy
SELLAS is focused on advancing its clinical-stage oncology pipeline toward regulatory milestones and potential partnering opportunities. The company’s strategy relies on generating clinical data for GPS and SLS009, while using licensing and collaboration agreements to support development and eventual commercialization.
Clinical data are needed to support a BLA and potential commercialization.
Diversifies the pipeline and creates a second oncology asset for partnering or development.
Partnerships can provide non-dilutive funding and commercialization reach.
Clinical-stage biotech requires ongoing capital to fund trials and operations.
Geography
SELLAS is headquartered in the United States and conducts its development and corporate activities from there. Its pipeline is intended for global oncology markets, and the company has referenced discussions with global and regional pharmaceutical companies for licensing and co-development.
Risks
SELLAS faces the typical risks of a clinical-stage oncology company: trial failure, regulatory delays, and uncertainty around whether its assets will achieve approval or market adoption. It also depends on external financing and partnering to fund development, which can be dilutive or unavailable on acceptable terms.
GPS and SLS009 are still in development, so efficacy or safety results may not support approval.
The company has historically funded operations through equity and convertible instruments.
Oncology products require successful clinical and regulatory review before commercialization.
Exposure: BLA preparation and FDA review
Future funding and market access may depend on licensing or co-development agreements.
Exposure: Global and regional pharma collaborations
Competing therapies may limit trial enrollment, pricing power, or eventual uptake.
Exposure: AML and broader cancer indications
Accounting
Judgemental itemsRevenue has been limited to the 3D Medicines Agreement, so contract timing and milestones can drive reported revenue.
Impact: Can create uneven revenue recognition across periods
Most development spending is expensed as incurred, making R&D the main operating cost.
Impact: Directly affects operating loss and period comparability
Registered direct offerings and warrant exercises are a major source of liquidity and can affect share count.
Impact: Impacts cash, equity, and dilution
Future operations depend on additional financing and successful development progress.
Impact: Important for assessing financial statement assumptions
Similar listed companies
Publicly listed companies with a comparable business focus.
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Terns Pharmaceuticals, Inc.
Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Silexion Therapeutics Corp
SLXNW · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Erasca, Inc.
ERAS · Pharmaceutical Preparations
Apollomics Inc.
APLMW · Pharmaceutical Preparations
Last updated: 24/09/2026